Sponsors › AstraZeneca

AstraZeneca

Every GLP‑1 and incretin trial, approval and scheduled result we hold for AstraZeneca, drawn from ClinicalTrials.gov and Drugs@FDA.

AstraZeneca is a commercial sponsor with 63 trials in the incretin class on file here, across 3 molecules. The programme is split between 14 early-stage trials and 49 in phase 3 or later. 85 approved FDA submissions sit against this sponsor in Drugs@FDA. The next scheduled result is 2028-05-23.

Molecules

exenatide · liraglutide · semaglutide

Trials on file

63

Active trials

1

Results scheduled

1

Approved FDA submissions

85

Results due

FDA record

Trials on file

All 63 incretin trials recorded for this sponsor, active first.